Author ORCID Identifier
0000-0002-0348-5475
Abstract
Hyponatremia is the most common electrolyte abnormality inpatient. Medications are a common cause of this. Cancer treatment has evolved with immune check point inhibitors replacing conventional chemotherapy agents. Pembrolizumab, which is a program cell death receptor-1 ligand has been shown to cause endocrinopathies. We describe a case of hyponatremia due to pembrolizumab
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Recommended Citation
Reghis M, Gowdar T, Sekar A. Pembrolizumab induced hyponatremia. A case report. Advances in Clinical Medical Research and Healthcare Delivery. 2024; 4(3). doi: 10.53785/2769-2779.1237.
Included in
Endocrinology, Diabetes, and Metabolism Commons, Internal Medicine Commons, Nephrology Commons